Which company develops gosatuzumab (Tudavi) and its brand background?

Gosatuzumab (Trodelvy) is an innovative antibody drug conjugate (ADC), mainly used to treat metastatic triple-negative breast cancer and other solid tumors. By targeting the Trop-2 protein on the surface of tumor cells, the drug delivers cytotoxic drugs directly into cancer cells to achieve precise killing while minimizing damage to normal cells. The emergence of Tudavi brings new treatment hope to patients with refractory breast cancer.

Gosatuzumab was originally developed by the US biopharmaceutical companyImmunomedics. Immunomedics is an innovative company focusing on the research and development of antibody conjugate drugs. It has rich research and development experience and technology accumulation in the anti-tumor field. In 2020, Immunomedics was acquired by Gilead Sciences (Gilead Sciences), a large American biopharmaceutical company. Gilead took over the research and development and commercialization of Tudavi, which accelerated its promotion and application on a global scale.

In the Asian market, Tudavi was initially developed and commercialized by Everest Medicines (Everest Medicines). In 2019, Genting Xinyao signed an agreement with Immunomedics and obtained the exclusive development and sales rights of Tuodawei in Greater China, South Korea, Singapore and other regions. This collaboration enables Tudavi to better enter the Asian market, meet the clinical needs of local patients, and promote clinical research and registration of the drug in the Asia-Pacific region.

However, in August 2022, Gilead Sciences reached an agreement with Genting Xinyao to take back the development and commercialization rights of Tudavi in the above-mentioned Asian regions, and Gilead will be directly responsible for the management and operation. This change reflects Gilead’s adjustment in its global market strategy, and also reflects the ability of multinational pharmaceutical companies to flexibly respond to markets and partnerships in international drug promotion. Overall, Tudavi's brand background combines the R&D advantages of innovative small companies with the global resources of large pharmaceutical companies, promoting its rapid development in the field of cancer treatment.

Reference: https://go.drugbank.com/drugs/